Provider and patient attitudes vary, but there exists much more reluctance to initiate pharmacotherapy for obesity than for other chronic diseases such as hypertension, type 2 diabetes, or hyperlipidemia
[DOI] [PubMed] [Google Scholar] 223.Yamada S
Microdosing reframes this process as something entirely separate, even though the safer, evidence-based options already exist within standard care
Follow-up measurements taken during the 90 days on either side of these post-index dates were valid, with the closest measurement to 180/365 days post-index used as the follow-up value if multiple measurements were available
This ensures GLP-1 therapy is right for you
We describe cosmetic appearance outcomes only: skin that looks smoother, with a firmer appearance over weeks of consistent use